ArticleFrontiers in oncology2023

Refractory microsatellite stable metastatic colorectal cancer with ERBB2/ERBB3 mutation may be preferred population for regorafenib plus PD-1 inhibitor therapy: a real-world study.

Xuan Dai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.